Synthesis and Evaluation as PDE4 Inhibitors of Pyrimidine-2,4-dione Derivatives

被引：3

作者：

Giovannoni, Maria P. ^{[1
]}

Graziano, Alessia ^{[1
]}

Matucci, Rosanna ^{[2
]}

Nesi, Marta ^{[2
]}

Cesari, Nicoletta ^{[1
]}

Vergelli, Claudia ^{[1
]}

Biancalani, Claudio ^{[1
]}

Crocetti, Letizia ^{[1
]}

Cilibrizzi, Agostino ^{[1
]}

Dal Piaz, Vittorio ^{[1
]}

机构：

[1] Dipartimento Sci Farmaceut, I-50019 Florence, Italy

[2] Dipartimento Farmacol Preclin & Clin MA Mancini, Florence, Italy

来源：

DRUG DEVELOPMENT RESEARCH | 2011年 / 72卷 / 03期

关键词：

HARBS; PDE4; selectivity; CROSS-COUPLING REACTIONS; PHOSPHODIESTERASE-4; INHIBITORS; C-N; POTENT; ROLIPRAM; BINDING; SUPPRESSION; THALIDOMIDE; EXPRESSION; ANALOGS;

D O I：

10.1002/ddr.20395

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of nitraquazone analogs with a pyrimidindione core was synthesized and tested for inhibitory activity on PDE4, selectivity versus PDE3 and PDE5 and for affinity towards the rolipram high-affinity binding site (HARBS). The 5-anilino derivatives 13-18 showed the best profile combining appreciable PDE4 inhibitory activity (IC50 = 5-14 mu M) with a good selectivity toward PDE3 and PDE5. The same compounds demonstrate low affinity for the HARBS site with IC50 values of 12-69 mu M (IC50 for Rolipram = 3.6 nM). Drug Dev Res 72:274-288, 2011. (C) 2010 Wiley-Liss, Inc.

引用

页码：274 / 288

页数：15

共 52 条

[21]

Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753

[22] The potential role of roflumilast: The new phosphodiesterase-4 inhibitor [J].

Karish, Sarah B. ;

Gagnon, James M. .

ANNALS OF PHARMACOTHERAPY, 2006, 40 (06) :1096-1104

[23]

Khobzaoui Moussa, 2005, Curr Opin Investig Drugs, V6, P518

[24] Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease [J].

Lipworth, BJ .

LANCET, 2005, 365 (9454) :167-175

[25] Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents [J].

Lugnier, C .

PHARMACOLOGY & THERAPEUTICS, 2006, 109 (03) :366-398

[26] Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells [J].

MacKenzie, SJ ;

Houslay, MD .

BIOCHEMICAL JOURNAL, 2000, 347 (pt 2) :571-578

[27] Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site [J].

Martin, C ;

Göggel, R ;

Dal Piaz, V ;

Vergelli, C ;

Giovannoni, MP ;

Ernst, M ;

Uhlig, S .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (04) :284-289

[28] Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells [J].

Mata, M ;

Sarriá, B ;

Buenestado, A ;

Cortijo, J ;

Cerdá, M ;

Morcillo, EJ .

THORAX, 2005, 60 (02) :144-152

[29] SELECTIVE OXIDATIVE HALOGENATION OF URACILS [J].

MOLTKELETH, C ;

JORGENSEN, KA .

ACTA CHEMICA SCANDINAVICA, 1993, 47 (11) :1117-1121

[30] Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa [J].

Morelli, A ;

Filippi, S ;

Mancina, R ;

Luconi, M ;

Vignozzi, L ;

Marini, M ;

Orlando, C ;

Vannelli GB ;

Aversa, A ;

Natali, A ;

Forti, G ;

Giorgi, M ;

Jannini, EA ;

Ledda, F ;

Maggi, M .

ENDOCRINOLOGY, 2004, 145 (05) :2253-2263

← 1 2 3 4 5 6 →